Clinical Trials


Moores Cancer Center boasts one third of the approximate 60 active immunotherapy focused clinical trials. Options are being investigated including chimeric antigen receptor (CAR) T-cell therapy, which uses patient immune response to eliminate abnormal cells through genetic modification; combination therapy for advanced cancers, which has shown a mix of checkpoint inhibitors and chemotherapy to be effective against typically resistant metastatic cancer in study models; and how modulating tumor microenvironments can achieve improved efficacy of checkpoint inhibitors.